Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

2.2K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.2K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

239
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
239
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

711
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
711
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

263
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
263
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

222
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
222
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

256
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
256

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report.

American journal of respiratory and critical care medicine·2026
Same author

Additive value of polygenic risk and family history for coronary heart disease risk stratification in two diverse US cohorts.

American journal of human genetics·2026
Same author

Genetic Determinants of Pulmonary Artery Size in over 50,000 Subjects with and without COPD.

medRxiv : the preprint server for health sciences·2026
Same author

Multi-ancestry modeling improves fine-mapping resolution, protein prediction, and discovery for proteome-wide association studies.

medRxiv : the preprint server for health sciences·2026
Same author

Atlas of glomerular disease-specific genetic effects on blood transcriptome.

medRxiv : the preprint server for health sciences·2026
Same author

Association of a Polygenic Risk Score with Diagnosis and Outcomes in Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Feb 7, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.8K

Age-dependent Genetic Risk in Pulmonary Fibrosis Patients and Relatives.

David Zhang1, Chad A Newton2, Imre Noth3

  • 1Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Columbia University Irving Medical Center, New York, NY.

Medrxiv : the Preprint Server for Health Sciences
|February 6, 2026
PubMed
Summary

Genetic risk factors for idiopathic pulmonary fibrosis (IPF) have age-dependent effects. Rare variants increase risk in younger individuals, while the MUC5B SNP increases risk in older individuals, impacting disease screening.

More Related Videos

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.1K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

948

Related Experiment Videos

Last Updated: Feb 7, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.8K
Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.1K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

948

Area of Science:

  • Genetics
  • Pulmonology
  • Age-related diseases

Background:

  • Idiopathic pulmonary fibrosis (IPF) is an age-related lung disease with known genetic risk factors.
  • The influence of these genetic factors on IPF risk across different age groups remains unclear.

Purpose of the Study:

  • To investigate how common and rare genetic risk factors for pulmonary fibrosis (PF) affect disease risk differently based on patient age.
  • To analyze the interaction between age and genetic predisposition in IPF.

Main Methods:

  • Whole genome sequencing (WGS) was used to identify genetic risk factors in IPF cohorts (Columbia and TOPMed).
  • Age-stratified analyses were performed to assess the interaction between age and genetic risk.
  • Family studies (pedigrees) examined the age-specific prevalence of interstitial lung disease in relatives.

Main Results:

  • The risk associated with the MUC5B SNP increased with age, while the risk from rare variants decreased with age.
  • Significant interactions between age (particularly <55 years) and both MUC5B SNP and rare variants were observed.
  • Relatives in familial pulmonary fibrosis (FPF) families with rare variants showed earlier disease onset compared to those without.

Conclusions:

  • Age significantly modifies the impact of genetic risk factors in IPF.
  • Rare variants pose a higher risk in younger individuals, whereas the MUC5B SNP is more significant in older individuals.
  • Early disease prevalence in relatives of FPF patients with rare variants suggests potential for preclinical screening.